Back to today’s briefing

Story perspectives

Exenatide Trial Fails to Improve Parkinson's Symptoms

2/7/2025

23 4

Summary

Story summary

In a pivotal phase 3 trial, exenatide, a GLP-1 receptor agonist, failed to demonstrate any disease-modifying effects in 194 patients with Parkinson’s disease. Led by Thomas Foltynie from UCL, the study revealed no notable improvements in movement or symptom severity compared to a placebo, prompting researchers to consider targeted subgroups for future exploration.

1 of 1

Story summary

In a pivotal phase 3 trial, exenatide, a GLP-1 receptor agonist, failed to demonstrate any disease-modifying effects in 194 patients with Parkinson’s disease. Led by Thomas Foltynie from UCL, the study revealed no notable improvements in movement or symptom severity compared to a placebo, prompting researchers to consider targeted subgroups for future exploration.